Published in Cancer Weekly, September 7th, 2004
Aventis says it sees great promise for use of Taxotere in treating a variety of cancers. The company won FDA approval in May for using the drug as a prostate cancer treatment for men resistant to hormone therapy.
Aventis also plans to seek approval for Taxotere as a treatment for gastric cancer and head and neck...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.